{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T20:28:11Z","timestamp":1772828891466,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T00:00:00Z","timestamp":1699920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T00:00:00Z","timestamp":1699920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2703302"],"award-info":[{"award-number":["2022YFC2703302"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sichuan Province Science and Technology Support Program, China","award":["2021YFS0078"],"award-info":[{"award-number":["2021YFS0078"]}]},{"name":"Sichuan Province Science and Technology Support Program, China","award":["2022YFS0078"],"award-info":[{"award-number":["2022YFS0078"]}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["SCU2022F4080"],"award-info":[{"award-number":["SCU2022F4080"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pregnancy Childbirth"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Although the traditional contingent screening strategy is effective, there are still undetected low-risk trisomy 21. This study aims to define appropriate cut-off values of serum biochemical markers at low-risk and develop a strategy for sequential prenatal testing associated with first-trimester screening to increase the detection rate of trisomy 21.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was a 9-year retrospective analysis of singleton pregnant women who underwent serum biochemical screening or combined first-trimester screening (CFTS) in the first trimester. For the low-risk group, the cut-off values of the serum biochemical markers were adjusted to determine the appropriate detection efficiency. Gravidas with abnormal serum biochemical markers at low-risk were advised to undergo further non-invasive prenatal screening (NIPS), whereas others continued with routine prenatal care.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>When cut-off values of free beta subunit of human chorionic gonadotropin (free \u03b2-hCG) multiples of the median (MoM) or pregnancy-associated plasma protein A (PAPP-A) MoM were defined with \u2265\u20092.75 or \u2264\u20090.5, 7.72% (2,194\/28,405) in the serum biochemical screening group and 12.36% (4,005\/32,403) in CFTS group could be detected as abnormal results for further NIPS. Finally, 55.56% (5\/9) and 85.71% (6\/7) of trisomy 21 cases with false-negative results were detected, and the overall detection rate for trisomy 21 was improved by 10.64% (5\/47) and 12.77% (6\/47), respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The new contingent screening strategy can increase the detection rate of trisomy 21 compared with the traditional contingent screening strategy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12884-023-06115-1","type":"journal-article","created":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T12:02:10Z","timestamp":1699963330000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A new contingent screening strategy increased detection rate of trisomy 21 in the first trimester"],"prefix":"10.1186","volume":"23","author":[{"given":"Wei","family":"Luo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiwen","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lixing","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Pang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fene","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,14]]},"reference":[{"issue":"4","key":"6115_CR1","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1097\/AOG.0000000000004107","volume":"136","author":"Screening for Fetal Chromosomal Abnormalities","year":"2020","unstructured":"Screening for Fetal Chromosomal Abnormalities. ACOG Practice Bulletin Summary, Number 226. Obstet Gynecol. 2020;136(4):859\u201367.","journal-title":"Obstet Gynecol"},{"key":"6115_CR2","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ejogrb.2016.08.038","volume":"206","author":"A Kurtovic-Kozaric","year":"2016","unstructured":"Kurtovic-Kozaric A, Mehinovic L, Malesevic R, Mesanovic S, Jaros T, Stomornjak-Vukadin M, Mackic-Djurovic M, Ibrulj S, Kurtovic-Basic I, Kozaric M. Ten-year trends in prevalence of Down syndrome in a developing country: impact of the maternal age and prenatal screening. Eur J Obstet Gynecol Reprod Biol. 2016;206:79\u201383.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"1","key":"6115_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41572-019-0143-7","volume":"6","author":"SE Antonarakis","year":"2020","unstructured":"Antonarakis SE, Skotko BG, Rafii MS, Strydom A, Pape SE, Bianchi DW, Sherman SL, Reeves RH. Down syndrome. Nat Rev Dis Primers. 2020;6(1):9.","journal-title":"Nat Rev Dis Primers"},{"issue":"9","key":"6115_CR4","doi-asserted-by":"publisher","first-page":"e380","DOI":"10.1016\/j.jogc.2017.06.013","volume":"39","author":"D Chitayat","year":"2017","unstructured":"Chitayat D, Langlois S, Wilson RD. No. 261-Prenatal screening for fetal aneuploidy in Singleton pregnancies. J Obstet Gynaecol Can. 2017;39(9):e380\u201394.","journal-title":"J Obstet Gynaecol Can"},{"issue":"6","key":"6115_CR5","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1002\/pd.4103","volume":"33","author":"KH Nicolaides","year":"2013","unstructured":"Nicolaides KH, Syngelaki A, Gil M, Atanasova V, Markova D. Validation of targeted sequencing of single-nucleotide polymorphisms for non-invasive prenatal detection of aneuploidy of chromosomes 13, 18, 21, X, and Y. Prenat Diagn. 2013;33(6):575\u20139.","journal-title":"Prenat Diagn"},{"issue":"9","key":"6115_CR6","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1311037","volume":"370","author":"DW Bianchi","year":"2014","unstructured":"Bianchi DW, Parker RL, Wentworth J, Madankumar R, Saffer C, Das AF, Craig JA, Chudova DI, Devers PL, Jones KW, et al. DNA sequencing versus standard prenatal aneuploidy screening. N Engl J Med. 2014;370(9):799\u2013808.","journal-title":"N Engl J Med"},{"issue":"17","key":"6115_CR7","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1056\/NEJMoa1407349","volume":"372","author":"ME Norton","year":"2015","unstructured":"Norton ME, Jacobsson B, Swamy GK, Laurent LC, Ranzini AC, Brar H, Tomlinson MW, Pereira L, Spitz JL, Hollemon D, et al. Cell-free DNA analysis for noninvasive examination of trisomy. N Engl J Med. 2015;372(17):1589\u201397.","journal-title":"N Engl J Med"},{"issue":"1","key":"6115_CR8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/uog.15783","volume":"47","author":"MM Gil","year":"2016","unstructured":"Gil MM, Revello R, Poon LC, Akolekar R, Nicolaides KH. Clinical implementation of routine screening for fetal trisomies in the UK NHS: cell-free DNA test contingent on results from first-trimester combined test. Ultrasound Obstet Gynecol. 2016;47(1):45\u201352.","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"5","key":"6115_CR9","doi-asserted-by":"publisher","first-page":"374e371","DOI":"10.1016\/j.ajog.2012.08.033","volume":"207","author":"KH Nicolaides","year":"2012","unstructured":"Nicolaides KH, Syngelaki A, Ashoor G, Birdir C, Touzet G. Noninvasive prenatal testing for fetal trisomies in a routinely screened first-trimester population. Am J Obstet Gynecol. 2012;207(5):374e371\u2013376.","journal-title":"Am J Obstet Gynecol"},{"issue":"12","key":"6115_CR10","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1002\/pd.3974","volume":"32","author":"P Guanciali-Franchi","year":"2012","unstructured":"Guanciali-Franchi P, Iezzi I, Soranno A, de Volo CP, Alfonsi M, Calabrese G, Benn P. Optimal cut-offs for Down syndrome contingent screening in a population of 10,156 pregnant women. Prenat Diagn. 2012;32(12):1147\u201350.","journal-title":"Prenat Diagn"},{"issue":"8","key":"6115_CR11","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1038\/gim.2017.188","volume":"20","author":"NJ Wald","year":"2018","unstructured":"Wald NJ, Huttly WJ, Bestwick JP, Old R, Morris JK, Cheng R, Aquilina J, Peregrine E, Roberts D, Alfirevic Z. Prenatal reflex DNA screening for trisomies 21, 18, and 13. Genet Med. 2018;20(8):825\u201330.","journal-title":"Genet Med"},{"issue":"24","key":"6115_CR12","first-page":"2905","volume":"30","author":"E Colosi","year":"2017","unstructured":"Colosi E, D\u2019Ambrosio V, Periti E. First trimester contingent screening for trisomies 21,18,13: is this model cost efficient and feasible in public health system? J Matern Fetal Neonatal Med. 2017;30(24):2905\u201310.","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"22","key":"6115_CR13","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1080\/14767058.2017.1362383","volume":"31","author":"C Charoenratana","year":"2018","unstructured":"Charoenratana C, Wanapirak C, Sirichotiyakul S, Tongprasert F, Srisupundit K, Luewan S, Tongsong T. Optimal risk cut-offs for Down syndrome contingent maternal serum screening. J Matern Fetal Neonatal Med. 2018;31(22):3009\u201313.","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"6","key":"6115_CR14","doi-asserted-by":"publisher","first-page":"e0218166","DOI":"10.1371\/journal.pone.0218166","volume":"14","author":"F Prefumo","year":"2019","unstructured":"Prefumo F, Paolini D, Speranza G, Palmisano M, Dionisi M, Camurri L. The contingent use of cell-free fetal DNA for prenatal screening of trisomies 21, 18, 13 in pregnant women within a national health service: a budget impact analysis. PLoS ONE. 2019;14(6):e0218166.","journal-title":"PLoS ONE"},{"issue":"5","key":"6115_CR15","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1007\/s00404-020-05846-2","volume":"303","author":"P Quaresima","year":"2020","unstructured":"Quaresima P, Visconti F, Greco E, Venturella R, Di Carlo C. Prenatal tests for chromosomal abnormalities detection (PTCAD): pregnant women\u2019s knowledge in an Italian Population. Arch Gynecol Obstet. 2020;303(5):1185\u201390.","journal-title":"Arch Gynecol Obstet"},{"key":"6115_CR16","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa043693","volume":"353","author":"FC Malone","year":"2005","unstructured":"Malone FC, Ball JA. First- and second-trimester evaluation of risk (FASTER) Research Consortium: first-trimester or second-trimester screening, or both, for Down\u2019s syndrome. N Engl J Med. 2005;353:2001\u201311.","journal-title":"N Engl J Med"},{"issue":"5","key":"6115_CR17","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1097\/AOG.0000000000001406","volume":"127","author":"Committee on Practice Bulletins-Obstetrics CoG","year":"2016","unstructured":"Committee on Practice Bulletins-Obstetrics CoG. The Society for maternal-fetal M: practice Bulletin No. 163: screening for fetal aneuploidy. Obstet Gynecol. 2016;127(5):e123\u2013137.","journal-title":"Obstet Gynecol"},{"issue":"1","key":"6115_CR18","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/uog.12511","volume":"42","author":"KH Nicolaides","year":"2013","unstructured":"Nicolaides KH, Wright D, Poon LC, Syngelaki A, Gil MM. First-trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell-free DNA testing. Ultrasound Obstet Gynecol. 2013;42(1):41\u201350.","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"3","key":"6115_CR19","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/uog.17484","volume":"50","author":"MM Gil","year":"2017","unstructured":"Gil MM, Accurti V, Santacruz B, Plana MN, Nicolaides KH. Analysis of cell-free DNA in maternal blood in screening for aneuploidies: updated meta-analysis. Ultrasound Obstet Gynecol. 2017;50(3):302\u201314.","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"12","key":"6115_CR20","doi-asserted-by":"publisher","first-page":"e0189235","DOI":"10.1371\/journal.pone.0189235","volume":"12","author":"P Guanciali Franchi","year":"2017","unstructured":"Guanciali Franchi P, Palka C, Morizio E, Sabbatinelli G, Alfonsi M, Fantasia D, Sitar G, Benn P, Calabrese G. Sequential combined test, second trimester maternal serum markers, and circulating fetal cells to select women for invasive prenatal diagnosis. PLoS ONE. 2017;12(12):e0189235.","journal-title":"PLoS ONE"},{"issue":"4","key":"6115_CR21","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/uog.18979","volume":"51","author":"A Lindquist","year":"2018","unstructured":"Lindquist A, Poulton A, Halliday J, Hui L. Prenatal diagnostic testing and atypical chromosome abnormalities following combined first-trimester screening: implications for contingent models of non-invasive prenatal testing. Ultrasound Obstet Gynecol. 2018;51(4):487\u201392.","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"12","key":"6115_CR22","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1002\/pd.4946","volume":"36","author":"M Kaijomaa","year":"2016","unstructured":"Kaijomaa M, Ulander VM, Hamalainen E, Alfthan H, Markkanen H, Heinonen S, Stefanovic V. The risk of adverse pregnancy outcome among pregnancies with extremely low maternal PAPP-A. Prenat Diagn. 2016;36(12):1115\u201320.","journal-title":"Prenat Diagn"},{"issue":"7","key":"6115_CR23","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1111\/jog.12662","volume":"41","author":"S Gupta","year":"2015","unstructured":"Gupta S, Goyal M, Verma D, Sharma A, Bharadwaj N, Kabra M, Kapoor S. Adverse pregnancy outcome in patients with low pregnancy-associated plasma protein-A: the Indian experience. J Obstet Gynaecol Res. 2015;41(7):1003\u20138.","journal-title":"J Obstet Gynaecol Res"},{"issue":"10","key":"6115_CR24","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/S1701-2163(16)32973-5","volume":"30","author":"A Gagnon","year":"2008","unstructured":"Gagnon A, Wilson RD, Society Of O, Gynaecologists Of Canada Genetics C. Obstetrical Complications associated with abnormal maternal serum markers analytes. J Obstet Gynaecol Can. 2008;30(10):918\u201332.","journal-title":"J Obstet Gynaecol Can"},{"issue":"10","key":"6115_CR25","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1080\/14767058.2018.1529162","volume":"33","author":"W Pornwattanakrilert","year":"2020","unstructured":"Pornwattanakrilert W, Sekararithi R, Wanapirak C, Sirichotiyakul S, Tongprasert F, Srisupundit K, Luewan S, Tongsong T. First-trimester serum biomarker screening for fetal Down syndrome as a predictor of preterm delivery: a population-based study. J Matern Fetal Neonatal Med. 2020;33(10):1717\u201324.","journal-title":"J Matern Fetal Neonatal Med"}],"container-title":["BMC Pregnancy and Childbirth"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-023-06115-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12884-023-06115-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-023-06115-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T12:04:55Z","timestamp":1699963495000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpregnancychildbirth.biomedcentral.com\/articles\/10.1186\/s12884-023-06115-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,14]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["6115"],"URL":"https:\/\/doi.org\/10.1186\/s12884-023-06115-1","relation":{},"ISSN":["1471-2393"],"issn-type":[{"value":"1471-2393","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,14]]},"assertion":[{"value":"21 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was approved by the Medical Ethics Committee of West China Second University Hospital, Sichuan University, and all patients signed informed consent forms to participate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"791"}}